Abstract | BACKGROUND: OBJECTIVE: To describe the conditions of the use of micafungin in daily clinical practice and to evaluate its effectiveness and tolerability under real-world conditions. PATIENTS/METHODS: This observational, prospective, multicentre study was performed in 34 ICUs in France. The study population consisted of 275 patients ≥16 years old who received treatment with micafungin during the inclusion period. Dose and duration of treatment were at the discretion of the physician. RESULTS: Proven invasive candidiasis was documented before treatment in 106 patients (38.6%); 263 patients (95.6%) received the recommended dose (100 mg/day); 78 patients (28.8%) were treated for the recommended duration. A successful outcome was observed for 217 patients (79.2%). This proportion was significantly higher (83.3%; P < .0001) in patients treated for ≥14 days. Three patients discontinued treatment due to an adverse event considered related to micafungin. No clear impact of micafungin on hepatic function was observed. CONCLUSION:
Micafungin was effective in >75% of patients treated for IFIs in ICUs in France; outcomes may be improved with closer adherence to the recommended treatment duration.
|
Authors | Jean-François Timsit, Guy Leverger, Noël Milpied, Bertrand Gachot |
Journal | Mycoses
(Mycoses)
Vol. 63
Issue 5
Pg. 443-451
(May 2020)
ISSN: 1439-0507 [Electronic] Germany |
PMID | 32048344
(Publication Type: Journal Article, Multicenter Study, Observational Study)
|
Copyright | © 2020 Blackwell Verlag GmbH. |
Chemical References |
- Antifungal Agents
- Micafungin
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antifungal Agents
(therapeutic use)
- Candidiasis, Invasive
(drug therapy)
- Female
- France
- Humans
- Intensive Care Units
- Invasive Fungal Infections
(drug therapy)
- Male
- Micafungin
(therapeutic use)
- Middle Aged
- Prospective Studies
- Treatment Outcome
- Young Adult
|